menu search

MDRX / Veradigm to Present at the 2023 J.P. Morgan Healthcare Conference

Veradigm to Present at the 2023 J.P. Morgan Healthcare Conference
CHICAGO--( BUSINESS WIRE )--Veradigm Inc. (Nasdaq:MDRX), formerly Allscripts Healthcare Solutions Inc., announced today that Rick Poulton, Veradigm Chief Executive Officer, will present at the 2023 J.P. Morgan Healthcare conference on Wednesday, January 11, 2023 at 3:45 PST. Read More
Posted: Jan 6 2023, 08:01
Author Name: Business Wire
Views: 110659

MDRX News  

Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity

By Zacks Investment Research
October 9, 2023

Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity

Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency. more_horizontal

Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery

By Zacks Investment Research
October 4, 2023

Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery

Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health. more_horizontal

Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes

By Zacks Investment Research
September 29, 2023

Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes

Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve. more_horizontal

Veradigm: Some Promise Combined With Uncertainty

By Seeking Alpha
September 22, 2023

Veradigm: Some Promise Combined With Uncertainty

Veradigm Inc. is a small-cap firm in the healthcare industry and its stock is trading near its 52-week low. The company was birthed out of Allscripts more_horizontal

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

By Zacks Investment Research
May 15, 2023

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances. more_horizontal

Will (MDRX) Beat Estimates Again in Its Next Earnings Report?

By Zacks Investment Research
February 3, 2023

Will (MDRX) Beat Estimates Again in Its Next Earnings Report?

(MDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its n more_horizontal

Strength Seen in Veradigm (MDRX): Can Its 5.0% Jump Turn into More Strength?

By Zacks Investment Research
January 12, 2023

Strength Seen in Veradigm (MDRX): Can Its 5.0% Jump Turn into More Strength?

Veradigm (MDRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the more_horizontal

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

By Zacks Investment Research
January 10, 2023

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances. more_horizontal


Search within

Pages Search Results: